
Crizocent250 mg
Incepta Pharmaceuticals Ltd.
Crizotinib is a tyrosine kinase inhibitor with established, FDA-approved indications in oncology.
Crizotinib is a tyrosine kinase inhibitor with established, FDA-approved indications in oncology. It is used based on confirmed biomarker status.
Important: ALK or ROS1 biomarker status must be confirmed by a validated test before starting Crizotinib, as efficacy depends entirely on this status. Crizotinib is not indicated in ALK-negative or ROS1-negative tumors.
Recommended dose: 250 mg orally twice daily, taken continuously until disease progression or unacceptable toxicity occurs.
Dosing is based on body surface area (BSA): 280 mg/m² orally twice daily (capsules or oral pellets, depending on ability to swallow capsules), with dose selected from a body-surface-area-based dosing table, continued until disease progression or unacceptable toxicity.
| Renal Function | Dose Adjustment |
|---|---|
| Mild to moderate impairment (CrCl ≥30 mL/min) | No dose adjustment needed |
| Severe impairment (CrCl <30 mL/min) not requiring dialysis | Reduce to 250 mg once daily (adult NSCLC dosing) |
Missed dose: If a dose is missed, it should be taken as soon as remembered unless it is less than 6 hours until the next dose, in which case the missed dose should be skipped.
See Administration and Dosage sections below for further details, and Use in Special Populations for hepatic impairment guidance.
The most common adverse reactions (occurring in ≥25% of patients) associated with Crizotinib in NSCLC trials include:
Serious but less common reactions include hepatotoxicity, interstitial lung disease/pneumonitis, QT prolongation, bradycardia, and severe visual loss - see Precautions and Warnings for detail. In pediatric ALCL/IMT patients, gastrointestinal toxicity (nausea, vomiting, diarrhea) is very common, and myelosuppression (neutropenia, lymphopenia, thrombocytopenia) can occur.
Crizotinib is contraindicated in patients with known hypersensitivity to Crizotinib or to any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.